Once again, the U.K. government and Vertex Pharmaceuticals (VRTX) appear to be at an impasse over pricing and access for a pricey medicine, a long-running battle that has become a symbol of the sometimes fierce clashes between drug makers and cash-strapped governments.

On Thursday, the drug maker issued a statement expressing “disappointment” with a recent response from the official cost-effectiveness watchdog, which deemed the Orkambi cystic fibrosis treatment is not worth what Vertex seeks to charge. And there was no indication when discussions may resume.

Continue to STAT Plus to read the full story…

Source link